ENvue Medical, Inc.

CIK 1326706 FEED·Manufacturing · All EDGAR filings ↗

Refine

An amendment is grouped with the report it amends; every 12b-25 notice is one group

Late filing Filing comparison 2026-08-14

ENvue Medical, Inc. told the SEC it could not file its quarterly report on time

Does not expect a significant change in results. Filed on the statutory due date.

(the “Company”) will not, without unreasonable effort and expense, be able to file its Quarterly Report on Form 10-Q for the period ended June 30, 2026 (the “Form 10-Q”), within the prescribed time period. Additional time is needed for the Company to prepare, compile and analyze supporting documentation in order to complete its disclosures and financial statement preparation and review process to finalize the Form 10-Q. The Company anticipates that it will file the Form 10-Q no later than the fifth calendar day following the prescribed filing date.

Evidence

Anticipates significant change: No
Days past due date: 0
Routine: Yes
Severity: normal
Source: Form 12b-25 (notification of late filing)
Stated reason: (the “Company”) will not, without unreasonable effort and expense, be able to file its Quarterly Report on Form 10-Q for the period ended June 30, 2026 (the “Form 10-Q”), within the prescribed time period. Additional time is needed for the Company to prepare, compile and analyze supporting documentation in order to complete its disclosures and financial statement preparation and review process to finalize the Form 10-Q. The Company anticipates that it will file the Form 10-Q no later than the fifth calendar day following the prescribed filing date.
Why: The company told the SEC it could not file a periodic report on time, using Form 12b-25.

Source filing ↗

Late filing Filing comparison 2026-05-15

ENvue Medical, Inc. told the SEC it could not file its quarterly report on time

Does not expect a significant change in results. Filed on the statutory due date.

(the “Company”) will not, without unreasonable effort and expense, be able to file its Quarterly Report on Form 10-Q for the period ended March 31, 2026 (the “Form 10-Q”), within the prescribed time period. Additional time is needed for the Company to prepare, compile and analyze supporting documentation in order to complete its disclosures and financial statement preparation and review process to finalize the Form 10-Q. The Company anticipates that it will file the Form 10-Q no later than the fifth calendar day following the prescribed filing date.

Evidence

Anticipates significant change: No
Days past due date: 0
Routine: Yes
Severity: normal
Source: Form 12b-25 (notification of late filing)
Stated reason: (the “Company”) will not, without unreasonable effort and expense, be able to file its Quarterly Report on Form 10-Q for the period ended March 31, 2026 (the “Form 10-Q”), within the prescribed time period. Additional time is needed for the Company to prepare, compile and analyze supporting documentation in order to complete its disclosures and financial statement preparation and review process to finalize the Form 10-Q. The Company anticipates that it will file the Form 10-Q no later than the fifth calendar day following the prescribed filing date.
Why: The company told the SEC it could not file a periodic report on time, using Form 12b-25.

Source filing ↗

Revenue recognition change beta Filing comparison 2026-04-15

ENvue Medical, Inc. changed its revenue recognition disclosure

The Company’s performance obligation is generally the sale and delivery of its products.

Evidence

New language: The Company’s performance obligation is generally the sale and delivery of its products., Regarding its ENvue product sales, the Company regularly sells its Systems and Nasoenteral tubes on a stand-alone basis and therefore concludes these products are separate performance obligations., When a contract includes one performance obligation, the entire transaction price is allocated to that performance obligation.
Prior filed: 2025-03-31
Prior form: 10-K
Similarity: 0.202
Source: revenue recognition note comparison
Threshold: 0.6
Why: The revenue recognition policy disclosure changed materially from the previous comparable filing.

Language present now, absent from the prior filing:

The Company’s performance obligation is generally the sale and delivery of its products.
Regarding its ENvue product sales, the Company regularly sells its Systems and Nasoenteral tubes on a stand-alone basis and therefore concludes these products are separate performance obligations.
When a contract includes one performance obligation, the entire transaction price is allocated to that performance obligation.

Source filing ↗ Prior filing ↗

Late filing elevated Filing comparison 2026-03-31

ENvue Medical, Inc. told the SEC it could not file its annual report on time

Does not expect a significant change in results. Filed on the statutory due date.

(the “Company”) is unable, without unreasonable effort or expense, to file its Annual Report on Form 10-K for the fiscal year ended December 31, 2025 (the “Form 10-K”) within the time period, as the Company requires additional time to review the information required to be included in the Form 10-K, including the financial statements, for the fourth quarter and fiscal year ended December 31, 2025. The Company expects to file the Form 10-K within the extension period of 15 calendar days, as provided under Rule 12b -25 promulgated under the Securities Exchange Act of 1934, as amended.

Evidence

Anticipates significant change: No
Days past due date: 0
Routine: No
Severity: elevated
Source: Form 12b-25 (notification of late filing)
Stated reason: (the “Company”) is unable, without unreasonable effort or expense, to file its Annual Report on Form 10-K for the fiscal year ended December 31, 2025 (the “Form 10-K”) within the time period, as the Company requires additional time to review the information required to be included in the Form 10-K, including the financial statements, for the fourth quarter and fiscal year ended December 31, 2025. The Company expects to file the Form 10-K within the extension period of 15 calendar days, as provided under Rule 12b -25 promulgated under the Securities Exchange Act of 1934, as amended.
Why: The company told the SEC it could not file a periodic report on time, using Form 12b-25.

Source filing ↗